Capricor Therapeutics (CAPR) Competitors $5.81 -0.47 (-7.48%) As of 01:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CAPR vs. SPRY, PHVS, RCUS, ZYME, GPCR, CRMD, LENZ, SION, STOK, and MLYSShould you be buying Capricor Therapeutics stock or one of its competitors? The main competitors of Capricor Therapeutics include ARS Pharmaceuticals (SPRY), Pharvaris (PHVS), Arcus Biosciences (RCUS), Zymeworks (ZYME), Structure Therapeutics (GPCR), CorMedix (CRMD), LENZ Therapeutics (LENZ), Sionna Therapeutics (SION), Stoke Therapeutics (STOK), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical products" industry. Capricor Therapeutics vs. Its Competitors ARS Pharmaceuticals Pharvaris Arcus Biosciences Zymeworks Structure Therapeutics CorMedix LENZ Therapeutics Sionna Therapeutics Stoke Therapeutics Mineralys Therapeutics Capricor Therapeutics (NASDAQ:CAPR) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends. Which has more volatility & risk, CAPR or SPRY? Capricor Therapeutics has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, ARS Pharmaceuticals has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Does the media refer more to CAPR or SPRY? In the previous week, Capricor Therapeutics had 12 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 23 mentions for Capricor Therapeutics and 11 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 1.46 beat Capricor Therapeutics' score of 0.40 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 17 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral ARS Pharmaceuticals 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is CAPR or SPRY more profitable? ARS Pharmaceuticals has a net margin of -42.74% compared to Capricor Therapeutics' net margin of -181.71%. ARS Pharmaceuticals' return on equity of -21.85% beat Capricor Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Capricor Therapeutics-181.71% -62.71% -50.82% ARS Pharmaceuticals -42.74%-21.85%-15.88% Do insiders & institutionals have more ownership in CAPR or SPRY? 21.7% of Capricor Therapeutics shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 10.5% of Capricor Therapeutics shares are owned by insiders. Comparatively, 33.5% of ARS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts prefer CAPR or SPRY? Capricor Therapeutics currently has a consensus target price of $22.56, indicating a potential upside of 291.66%. ARS Pharmaceuticals has a consensus target price of $32.50, indicating a potential upside of 211.75%. Given Capricor Therapeutics' higher possible upside, analysts plainly believe Capricor Therapeutics is more favorable than ARS Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Capricor Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11ARS Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Which has preferable valuation and earnings, CAPR or SPRY? ARS Pharmaceuticals has higher revenue and earnings than Capricor Therapeutics. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCapricor Therapeutics$22.27M11.82-$40.47M-$1.64-3.51ARS Pharmaceuticals$89.15M11.56$8M-$0.49-21.28 SummaryARS Pharmaceuticals beats Capricor Therapeutics on 11 of the 16 factors compared between the two stocks. Get Capricor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CAPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CAPR vs. The Competition Export to ExcelMetricCapricor TherapeuticsMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$261.93M$10.80B$5.75B$9.85BDividend YieldN/A1.84%6.66%4.49%P/E Ratio-3.4921.6682.7926.52Price / Sales11.8228.09499.49162.43Price / CashN/A25.1325.7028.92Price / Book2.503.3910.786.50Net Income-$40.47M$211.94M$3.28B$266.34M7 Day Performance-8.00%-4.12%-0.42%-1.25%1 Month Performance-25.01%6.85%6.47%3.30%1 Year Performance32.39%-8.71%49.47%23.59% Capricor Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CAPRCapricor Therapeutics2.8924 of 5 stars$5.81-7.5%$22.56+288.2%+43.7%$264.72M$22.27M-3.53101SPRYARS Pharmaceuticals3.0392 of 5 stars$11.62-9.6%$31.00+166.8%-8.9%$1.15B$89.15M-23.7190News CoveragePositive NewsAnalyst ForecastHigh Trading VolumePHVSPharvaris2.8754 of 5 stars$21.65-5.2%$35.60+64.4%+24.8%$1.13BN/A-6.4430RCUSArcus Biosciences2.085 of 5 stars$10.60-0.1%$21.14+99.6%-29.8%$1.13B$258M-3.34500News CoveragePositive NewsZYMEZymeworks0.1132 of 5 stars$14.81-0.2%N/AN/A$1.11B$76.30M-15.27460News CoverageGPCRStructure Therapeutics2.5562 of 5 stars$19.30+0.8%$75.71+292.3%-48.4%$1.11BN/A-18.38136Positive NewsCRMDCorMedix3.5376 of 5 stars$14.83+3.3%$17.33+16.9%+134.6%$1.11B$43.47M19.7730Short Interest ↑LENZLENZ Therapeutics1.789 of 5 stars$38.63+1.1%$49.60+28.4%+72.8%$1.10BN/A-20.33110Positive NewsSIONSionna Therapeutics1.8378 of 5 stars$24.62-4.3%$38.50+56.4%N/A$1.09BN/A0.0035News CoverageAnalyst ForecastInsider TradeSTOKStoke Therapeutics4.5227 of 5 stars$19.76-0.1%$25.57+29.4%+31.5%$1.08B$36.56M23.25100News CoverageInsider TradeMLYSMineralys Therapeutics1.8432 of 5 stars$15.48+1.7%$34.40+122.2%+144.8%$1.03BN/A-4.3528News CoverageAnalyst Forecast Related Companies and Tools Related Companies SPRY Competitors PHVS Competitors RCUS Competitors ZYME Competitors GPCR Competitors CRMD Competitors LENZ Competitors SION Competitors STOK Competitors MLYS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CAPR) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersThis Massive Market is Ripe for Disruption by this NasdaqFanatics Hit $31B. This Nasdaq Company Is Building the Next Wave Fanatics built a merch empire by owning th...i2i Marketing Group, LLC | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored“Shadow Group” in Washington, DC Could Crash MarketNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capricor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
